Conjugate Of Galnac And Saponin, Therapeutic Composition Comprising Said Conjugate And A Galnac-Oligonucleotide Conjugate - EP4171641

The patent EP4171641 was granted to Sapreme on Oct 30, 2024. The application was originally filed on Jun 18, 2021 under application number EP21734241A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4171641

SAPREME
Application Number
EP21734241A
Filing Date
Jun 18, 2021
Status
Granted And Under Opposition
Sep 27, 2024
Grant Date
Oct 30, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJul 29, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2011054811
INTERNATIONAL-SEARCH-REPORTWO2020126604
OPPOSITIONWO2011054811

Non-Patent Literature (NPL) Citations (44) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- GOODING, MATT et al., Chemical biology & drug design, (20120000), vol. 80.6, pages 787 - 809-
DESCRIPTION- HERMANSON, GREG T., Bioconjugate techniques, Academic press, (20130000), page 289-
DESCRIPTION- J. Am. Chem Soc., (20140000), vol. 136, pages 16958 - 16961-
DESCRIPTION- SETTEN, RYAN L.JOHN J. ROSSISI-PING HAN, Nature Reviews Drug Discovery, (20190000), vol. 18.6, pages 421 - 446-
DESCRIPTION- Y ZHANGZ QUS KIMV SHIB LIA01,P KRAFTR BANDARUY WULM GREENBERGERID HORAK, "Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection", Gene Therapy, (20110000), vol. 18, doi:10.1038/gt.2010.133, pages 326 - 333, XP055412231
DESCRIPTION- B.G. NORDESTGAARD et al., "Advances in lipid-lowering therapy through gene-silencing technologies", Nature Reviews - Cardiology, (20180500), vol. 15, doi:10.1038/nrcardio.2018.3, pages 261 - 272, XP055721808
INTERNATIONAL-SEARCH-REPORT- BACHRAN CHRISTOPHER ET AL, "Saponins in Tumor Therapy", MINI-REVIEWS IN MEDICINAL CHEMISTRY, (20080801), vol. 8, pages 575 - 584, XP055775950 [A] 1-57-
INTERNATIONAL-SEARCH-REPORT- CHEENU BHARGAVA ET AL, "Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861", MOLECULAR ONCOLOGY, (20170915), vol. 11, no. 11, doi:10.1002/1878-0261.12115, ISSN 1574-7891, pages 1527 - 1543, XP055677214 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- GILABERT-ORIOL ROGER ET AL, "Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 66, no. 9, doi:10.1007/S00262-017-2013-Z, ISSN 0340-7004, (20170513), pages 1217 - 1228, (20170513), XP036309505 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- ROGER GILABERT-ORIOL ET AL, "Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861", BIOCHEMICAL PHARMACOLOGY, US, (20151001), vol. 97, no. 3, doi:10.1016/j.bcp.2015.07.040, ISSN 0006-2952, pages 247 - 255, XP055677222 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- ALEXANDER WENG ET AL, "The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins", MOLECULAR ONCOLOGY, ELSEVIER, vol. 6, no. 3, doi:10.1016/J.MOLONC.2012.01.004, ISSN 1574-7891, (20120112), pages 323 - 332, (20120124), XP028508748 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- SABINE SEWING ET AL, "GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells", MOLECULAR THERAPY: NUCLEIC ACIDS., US, (20190301), vol. 14, doi:10.1016/j.omtn.2018.11.005, ISSN 2162-2531, pages 67 - 79, XP055762603 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- ROGER GILABERT-ORIOL ET AL, "Modified Trastuzumab and Cetuximab Mediate Efficient Toxin Delivery While Retaining Antibody-Dependent Cell-Mediated Cytotoxicity in Target Cells", MOLECULAR PHARMACEUTICS, US, (20131007), vol. 10, no. 11, doi:10.1021/mp400444q, ISSN 1543-8384, pages 4347 - 4357, XP055677139 [A] 1-57
INTERNATIONAL-SEARCH-REPORT- HENDRIK FUCHS ET AL, "Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies", BIOMEDICINES, (20170329), vol. 5, no. 2, doi:10.3390/biomedicines5020014, page 14, XP055429235 [A] 1-57
OPPOSITION- Bachran Christopher, Bachran Silke, Sutherland Mark, Bachran Diana, Fuchs Hendrik, "Saponins in Tumor Therapy", Medicinal Chemistry, (20081231), pages 575 - 584, XP093128536-
OPPOSITION- D16a - Supplementary Information from D16 8 January 2020-
OPPOSITION- D17a - Online Supplementary Table from D17-
OPPOSITION- Cheenu Bhargava et al., "Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861", Mol Oncol, (20170915), vol. 11, no. 11, doi:10.1002/1878-0261.12115, pages 1527 - 1543, XP055677214
OPPOSITION- Yangbo Feng et al., "Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy", Cancer Med. , (20181106), vol. 7, doi:10.1002/cam4.1820, pages 6124 - 6136, XP093027357
OPPOSITION- Alberto Dal Corso; Luca Pignataro; Laura Belvisi; Cesare Gennari, "Innovative Linker Strategies for Tumor‐Targeted Drug Conjugates", Chemistry - A European Journal, John Wiley & Sons, Inc, DE, DE, (20190920), vol. 25, no. 65, doi:10.1002/chem.201903127, ISSN 0947-6539, pages 14740 - 14757, XP071850847
OPPOSITION- Roger Gilabert-Oriol et al., "Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma", Cancer Immunol Immunother., (20170513), vol. 66, no. 9, doi:10.1007/s00262-017-2013-z, pages 1217 - 1228, XP036309505
OPPOSITION- Greg T. Hermanson, "2. Functional Targets for Bioconjugation", Greg T. Hermanson, Greg T Hermanson, Bioconjugate Techniques, NL , Elsevier Science & Technology , (20130917), pages 127 - 228, doi:10.1016/B978-0-12-382239-0.00002-9, ISBN 978-0-12-382239-0, XP009562911
OPPOSITION- Greg T. Hermanson, "3. The Reactions of Bioconjugation", Greg T. Hermanson, Greg T Hermanson, Bioconjugate Techniques, NL , Elsevier Science & Technology , (20130917), pages 229 - 258, doi:10.1016/B978-0-12-382239-0.00003-0, ISBN 978-0-12-382239-0, XP009562910
OPPOSITION- Greg T. Hermanson, "Chapter 17 - Chemoselective Ligation; Bioorthogonal Reagents", Greg T. Hermanson, Greg T Hermanson, Bioconjugate Techniques, NL , Elsevier Science & Technology , (20130917), pages 757 - 786, doi:10.1016/B978-0-12-382239-0.00017-0, ISBN 978-0-12-382239-0, XP009562912
OPPOSITION- Xin Ming, Laing Brian, "Bioconjugates for targeted delivery of therapeutic oligonucleotides", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20150629), vol. 87, doi:10.1016/j.addr.2015.02.002, ISSN 0169-409X, pages 81 - 89, XP055346329
OPPOSITION- Roger Gilabert-Oriol et al., "Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861", Biochem Pharmacol, (20151001), vol. 97, no. 3, doi:10.1016/j.bcp.2015.07.040, pages 247 - 255, XP055677222
OPPOSITION- Potaczek Daniel P.; Garn Holger; Unger Sebastian D.; Renz Harald, "Antisense molecules: A new class of drugs", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20160504), vol. 137, no. 5, doi:10.1016/j.jaci.2015.12.1344, ISSN 0091-6749, pages 1334 - 1346, XP029531137
OPPOSITION- Alexander Weng et al., "Saponins modulate the intracellular trafficking of protein toxins", J Controlled Release, (20121010), vol. 164, doi:10.1016/j.jconrel.2012.10.002, pages 74 - 86, XP055428873
OPPOSITION- Alexander Weng et al., "The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins", Mol Oncol, (20120112), vol. 6, doi:10.1016/j.molonc.2012.01.004, page 3, XP028508748
OPPOSITION- Yuanyu Huang, "Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics", Molecular Therapy-Nucleic Acids, Cell Press, US, US , (20170301), vol. 6, doi:10.1016/j.omtn.2016.12.003, ISSN 2162-2531, pages 116 - 132, XP055485332
OPPOSITION- Sabine Sewing et al., "GalNAc conjugation attenuated the cytotoxicity of antisense oligonucleotide drugs in renal tubular cells", Mol Ther Nucleic Acids, (20190301), vol. 14, doi:10.1016/j.omtn.2018.11.005, XP055762603
OPPOSITION- Jan-Philip Meyer et al., "Click chemistry and radiochemistry: the First 10 years", Bioconjug Chem, (20161027), vol. 27, no. 12, doi:10.1021/acs.bioconjchem.6b00561, pages 2791 - 2807, XP055407064
OPPOSITION- Cao Xue-Wei, Wang Fu-Jun, Liew Oi-Wah, Lu Ye-Zhou, Zhao Jian, "Analysis of Triterpenoid Saponins Reveals Insights into Structural Features Associated with Potent Protein Drug Enhancement Effects", Molecular Pharmaceutics, American Chemical Society, US, US , doi:10.1021/acs.molpharmaceut.9b01158, ISSN 1543-8384, XP093304078
OPPOSITION- BIESSEN E.A.L.,ET AL., "Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes", Bioconjugate Chemistry - Author Manuscript, American Chemical Society, US, US , (20020101), vol. 13, doi:10.1021/bc015550g, ISSN 1043-1802, pages 295 - 302, XP002290397
OPPOSITION- Wakefield Darren H., Klein Jason J., Wolff Jon A., Rozema David B., "Membrane Activity and Transfection Ability of Amphipathic Polycations as a Function of Alkyl Group Size", Bioconjugate Chemistry - Author Manuscript, American Chemical Society, US, US , (20050901), vol. 16, no. 5, doi:10.1021/bc050067h, ISSN 1043-1802, pages 1204 - 1208, XP093304077
OPPOSITION- Roger Gilabert-Oriol et al., "Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells", Mol Pharm, (20131007), vol. 10, no. 11, doi:10.1021/mp400444q, pages 4347 - 4357, XP055677139
OPPOSITION- Bo Hu, et al., "Therapeutic siRNA: state of the art", Signal Transduct Target Ther, (20200619), vol. 5, doi:10.1038/s41392-020-0207-x, page 1, XP093147548
OPPOSITION- David B. Rozema, et al., "Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes", PNAS, (20070807), vol. 104, no. 32, doi:10.1073/pnas.0703778104, pages 12982 - 12987, XP055014142
OPPOSITION- Van Rossenberg Sabine, Sliedregt-Bol Karen M., Meeuwenoord Nico J., Van Berkel Theo J.C., Van Boom Jacques H., Van Der Marel Gijs A., Biessen Erik A.L., "Targeted Lysosome Disruptive Elements for Improvement of Parenchymal Liver Cell-specific Gene Delivery", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20021101), vol. 277, no. 48, doi:10.1074/jbc.M203510200, ISSN 0021-9258, pages 45803 - 45810, XP093304075
OPPOSITION- So C Wong, Klein Jason J, Hamilton Holly L, Chu Qili, Frey Christina L, Trubetskoy Vladimir S, Hegge Julia, Wakefield Darren, Rozema David B, Lewis David L, "Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo", Nucleic acid therapeutics, Mary Ann Liebert, Inc, United States, United States , doi:10.1089/nat.2012.0389, (20121201), pages 380 - 390, Nucleic acid therapeutics, URL: http://online.liebertpub.com/doi/pdf/10.1089/nat.2012.0389, (20160330), XP055261447
OPPOSITION- Aaron D. Springer, Steven F. Dowdy, "GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics", Nucleic Acid Therapeutics, Mary Ann Liebert, Inc. Publishers, US, US , (20180601), vol. 28, no. 3, doi:10.1089/nat.2018.0736, ISSN 2159-3337, pages 109 - 118, XP055555952
OPPOSITION- Rudolph L. Juliano, "The delivery of therapeutic oligonucleotides", Nucleic Acid Res, (20160415), vol. 44, no. 14, doi:10.1093/nar/gkw236, pages 6518 - 6548, XP055491290
OPPOSITION- Jorine M. Eeftens, Jaco Van Der Torre, Daniel R. Burnham, Cees Dekker, "Copper-free click chemistry for attachment of biomolecules in magnetic tweezers", BMC Biophysics, PhysMed Central, (20151225), vol. 8, no. 1, doi:10.1186/s13628-015-0023-9, XP055432659
OPPOSITION- Hendrik Fuchs, et al., "Glycosylated triterpenoids as endosomal escape enhancers in targeted tumor therapies", Biomedicines, (20170329), vol. 5, no. 2, doi:10.3390/biomedicines5020014, page 14, XP055429235

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents